MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617094962 A) filed by Paul Scherrer Institut on August 05, 2026, for Radiolabeled Complexes And Pharmaceutical Compositions Including The Same.
Inventors include Schibli, Roger; Mller, Cristina; Vaccarin, Christian; Beyer, Darja; and Deberle, Luisa Maria.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The present invention provides novel compounds having a prolonged blood circulation time that are useful as radiopharmaceuticals, imaging agents and for treatment or diagnosis of cancer. In one embodiment, the present invention provides a radiolabeled complex targeting the urokinase-type plasminogen activator receptor (uPAR) comprising (a) a targeting peptide moiety binding the urokinase-type plasminogen activator receptor (uPAR), (b) a chelating moiety, (c) a radionuclide, and (d) an albumin-binding moiety, wherein the targeting peptide moiety, the chelating moiety and the albumin-binding moiety are linked via a common trifunctional linker moiety (L1). In a preferred embodiment, the targeting peptide moiety comprises the amino acid sequence (Asp)-([beta]-cyclohexyl-L-alanine)-(Phe)-(D-Ser)-(D-Arg)- (Tyr)-(Leu)-(Trp)-(Ser), the chelating moiety is DOTA and the albumin-binding moiety is an iodophenyl or tolyl moiety.
Disclaimer: Curated by HT Syndication.
